Search
2026
2025
2024
2023
-
Feb 19, 2026
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin DeficiencyRead More
-
Feb 02, 2026
YolTech Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation to YOLT-203 for the Treatment of Primary Hyperoxaluria Type 1Read More
-
Nov 19, 2025
YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)Read More
-
Sep 11, 2025
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICCRead More
-
Jul 28, 2025
YOLT-203 Receives Orphan Drug Designation from EMARead More
